| Literature DB >> 34372505 |
Sarah Bailly1, Dominique Rousset2, Camille Fritzell1, Nathanaël Hozé3, Sarrah Ben Achour2, Léna Berthelot2, Antoine Enfissi2, Jessica Vanhomwegen4, Henrik Salje3,5, Sandrine Fernandes-Pellerin6, Mona Saout1, Anne Lavergne2, Jean-Claude Manuguerra4, Jean-François Carod7, Félix Djossou8, Simon Cauchemez3, Claude Flamand1,3.
Abstract
Despite the health, social and economic impact of arboviruses in French Guiana, very little is known about the extent to which infection burden is shared between individuals. We conducted a large multiplexed serological survey among 2697 individuals from June to October 2017. All serum samples were tested for IgG antibodies against DENV, CHIKV, ZIKV and MAYV using a recombinant antigen-based microsphere immunoassay with a subset further evaluated through anti-ZIKV microneutralization tests. The overall DENV seroprevalence was estimated at 73.1% (70.6-75.4) in the whole territory with estimations by serotype at 68.9% for DENV-1, 38.8% for DENV-2, 42.3% for DENV-3, and 56.1% for DENV-4. The overall seroprevalence of CHIKV, ZIKV and MAYV antibodies was 20.3% (17.7-23.1), 23.3% (20.9-25.9) and 3.3% (2.7-4.1), respectively. We provide a consistent overview of the burden of emerging arboviruses in French Guiana, with useful findings for risk mapping, future prevention and control programs. The majority of the population remains susceptible to CHIKV and ZIKV, which could potentially facilitate the risk of further re-emergences. Our results underscore the need to strengthen MAYV surveillance in order to rapidly detect any substantial changes in MAYV circulation patterns.Entities:
Keywords: Chikungunya; Dengue; French Guiana; Mayaro; Zika; arboviruses; prevalence studies
Mesh:
Substances:
Year: 2021 PMID: 34372505 PMCID: PMC8310293 DOI: 10.3390/v13071299
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1Map of French Guiana with geographical areas.
Description of the household selection process and weighted seroprevalence estimated by municipality.
| Municipality (i) | Population | No. of Households | No.(%) of Enrolled Households | No. of Enrolled Individuals | DENV Weighted Seroprevalence | CHIKV Weighted Seroprevalence | Zika Weighted Seroprevalence | Mayaro Weighted Seroprevalence |
|---|---|---|---|---|---|---|---|---|
| Cayenne | 57,614 | 21,659 | 196 (0.9%) | 446 | 72.0 (66.7–76.7) | 18.1 (13.0–24.7) | 25.2 (20.2–30.9) | 1.4 (0.6–3.0) |
| Matoury | 32,427 | 10,778 | 136 (1.3%) | 265 | 76.8 (69.7–82.6) | 16.2 (11.0–23.1) | 22.7 (16.5–30.5) | 2.0 (0.9–4.4) |
| Saint-Laurent | 43,600 | 9770 | 170 (1.7%) | 301 | 78.0 (71.7–83.2) | 32.1 (24.2–41.2) | 32.4 (25.7–39.9) | 9.1 (6.2–13.0) |
| Kourou | 26,221 | 8205 | 167 (2.0%) | 294 | 77.0 (70.2–82.6) | 28.3 [21.8–35.8) | 30.1 (23.8–37.3) | 2.3 (1.1–4.9) |
| Remire-Montjoly | 23,976 | 8117 | 105 (1.3%) | 192 | 69.9 (61.3–77.2) | 16.2 (9.7–26.0) | 13.7 (8.5–20.9) | 1.0 (0.2–4.2) |
| Macouria | 11,719 | 4218 | 75 (1.8%) | 164 | 66.0 (56.8–74.2) | 13.8 (7.8–23.3) | 10.9 (6.8–17.1) | 1.1 (0.3–4.6) |
| Mana | 10,241 | 2297 | 74 (3.2%) | 96 | 87.9 (78.1–93.7) | 33.0 (23.3–44.4) | 16.7 (10.6–25.4) | 11.5 (5.9–21.2) |
| Maripasoula | 11,856 | 1955 | 74 (3.8%) | 145 | 62.3 (51.2–72.3) | 13.7 (7.9–22.6) | 26.7 (16.6–40.0) | 13.6 (8.7–20.7) |
|
| . | . |
|
| 87.9 (75.2–94.5) | 22.3 (12.4–36–7) | 45.6 (30.0–62.0) | 12.2 (5.9–23.3) |
|
| . | . |
|
| 43.4 (32.1–55.3) | 6.9 (1.8–23.5) | 8.4 (2.6–24.0) | 15.5 (7.8–28.4) |
|
| . | . |
|
| 20.8 (10.3–37.5) | 0 | 0 | 15.1 (6.1–32.8) |
| Apatou | 8431 | 1839 | 45 (2.5%) | 62 | 81.5 (68.1–90.1) | 40.5 (29.2–52.9) | 19.1 (10.2–32.9) | 10.0 (4.7–20.3) |
| Grand-Santi | 6969 | 1447 | 28 (1.9%) | 61 | 79.6 (65.4–88.9) | 29.1 (17.6–44.0) | 17.1 (8.3–32.0) | 10.6 (4.8–21.7) |
| Saint-Georges | 4020 | 1208 | 32 (2.7%) | 86 | 77.6 (63.4–87.4) | 12.1 (4.2–30.3) | 27.6 (13.6–47.9) | 0.8 (0.1–5.3) |
| Papaïchton | 7266 | 1150 | 32 (2.8%) | 49 | 78.0 (52.9–91.8) | 50.3 (34.2–66.3) | 22.7 (11.1–40.8) | 8.5 (3.4–19.8) |
| Sinnamary | 2957 | 1092 | 30 (2.8%) | 39 | 79.1 (60.2–90.4) | 25.0 (10.2–49.5) | 37.4 (24.0–53.1) | 3.6 (0.5–22.0) |
| Roura | 3713 | 983 | 39 (4.0%) | 70 | 80.2 (68.2–88.5) | 9.7 (4.2–20.8) | 18.7 (9.7–32.9) | 1.0 (0.1–6.1) |
|
| . | . |
|
| 71.9 (57.3–83.0) | 13.3 (5.3–29.5) | 13.7 (5.1–31.7) | 0 |
|
| . | . |
|
| 94.8 (82.2–98.6) | 3.4 (0.5–19.5) | 27.3 (12.2–50.4) | 2.6 (0.5–13.3) |
| Montsinnery–Tonnegrande | 2473 | 898 | 29 (3.2%) | 66 | 59.0 (45.2–71.5) | 8.6 (2.2–28.5) | 10.7 (2.7–33.9) | 0.9 (0.1–6.1) |
| Iracoubo | 1878 | 585 | 29 (5.0%) | 53 | 78.1 (65.1–87.2) | 4.7 (0.6–28.1) | 10.7 (4.8–22.1) | 7.9 (2.6–22.1) |
| Regina | 946 | 401 | 43(10.7%) | 75 | 54.8 (42.6–66.5) | 5.4 (2.1–13.4) | 12.0 (5.8–23.4) | 5.2 (2.0–13.1) |
|
| . | . |
|
| 48.4 (36.6–60.3) | 6.3 (2.4–15.6) | 13.1 (5.9–26.3) | 6.1 (2.3–15.4) |
|
| . | . |
|
| 93.5 (63.6–99.2) | 0 | 5.9 (0.8–34.0) | 0 |
| Camopi | 1769 | 346 | 50 (14.5%) | 115 | 31.8 (22.7–42.6) | 1.6 (0.4–6.7) | 3.7 (1.3–9.8) | 19.2 (13.2–27.0) |
|
| . | . |
|
| 39.2 (27.7–52.1) | 2.3 (0.5–9.5) | 5.3 (2.0–13.5) | 17.4 (11.0–26.5) |
|
| . | . |
|
| 13.9 (7.0–25.7) | 0 | 0 | 23.5 (12.1–40.7) |
| Awala | 1379 | 330 | 28 (8.5%) | 60 | 54.3 (35.7–71.8) | 16.0 (7.5–31.1) | 25.5 (10.2–50.7) | 0 |
| Saint-Elie | 95 | 143 | 10 (7.0%) | 11 | 65.0 (32.6–87.7) | 0 | 0 | 30.5 (9.3–65.3) |
| Ouanary | 165 | 140 | 5 (3.6%) | 13 | 44.2 (11.8–82.4) | 23.3 (4.7–64.9) | 11.3 (3.0–34.5) | 0 |
| Saül | 150 | 94 | 18 (19.2%) | 34 | 55.4 (40.0–69.8) | 1.8 (0.2–13.3) | 2.1 (0.3–15.3) | 0 |
| Total | 259,865 | 77,655 | 1415 | 2697 | 73.1 (70.6–75.4) | 20.3 (17.7–23.1) | 23.3 (20.9–25.9) | 3.3 (2.7–4.1) |
Figure 2Spatial distribution of (a) DENV seroprevalence, (b) CHIKV seroprevalence, (c) ZIKV seroprevalence and (d) MAYV seroprevalence, French Guiana, 2017.
Figure 3Sample distribution of arboviruses infections and co-infections.
Factors associated with DENV, CHIKV and ZIKV seropositivity.
| Characteristic | DENV | CHIKV | ZIKV | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Weighted Prevalence % | Univariate | Multivariate | Weighted Prevalence % | Univariate | Multivariate | Weighted Prevalence % | Univariate | Multivariate | |
| (95% CI) | PR (95% CI) | PR (95% CI) | (95% CI) | PR (95% CI) | PR (95% CI) | (95% CI) | PR (95% CI) | PR (95% CI) | |
| Sex | |||||||||
| Male | 72.2 (68.7–75.5) | Ref | Ref | 18.5 (15.5–22.0) | Ref | Ref | 22.8 (19.5–26.5) | Ref | Ref |
| Female | 73.9 (70.8–76.7) | 1.0 (1.0–1.1) | 1.0 (0.9–1.0) | 22.0 (19.0–25.2) | 1.2 (1.0–1.4) * | 1.1 (1..0–1.3) | 23.8 (21.0–26.8) | 1.0 (0.9–1.2) | 1.0 (0.8–1.2) |
| Age, y | |||||||||
| 2–14 | 52.8 (47.1–58.3) | Ref | Ref | 18.0 (13.2–24.0) | Ref | Ref | 24.7 (19.8–30.3) | Ref | Ref |
| 15–24 | 76.9 (71.6–81.4) | 1.5 (1.3–1.6) *** | 1.5 (1.3–1.7) *** | 24.7 (19.9–30.3) | 1.4 (1.0–1.9) | 1.3 (0.9–1.7) | 25.9 (21.0–31.6) | 1.0 (0.8–1.4) | 1.0 (0.8–1.4) |
| 25–34 | 77.6 (72.7–81.8) | 1.5 (1.3–1.6) *** | 1.6 (1.4–1.8) *** | 23.1 (18.5–28.4) | 1.3 (0.9–1.7) | 1.2 (0.9–1.6) | 23.6 (19.2–28.7) | 0.9 (0.7–1.3) | 1.0 (0.7–1.3) |
| 35–44 | 79.1 (73.6–83.8) | 1.5 (1.3–1.7) *** | 1.7 (1.5–1.9) *** | 20.3 (16.0–25.4) | 1.1 (0.8–1.6) | 1.1 (0.8–1.5) | 19.7 (15.8–24.3) | 0.8 (0.6–1.1) | 0.8 (0.6–1.1) |
| 45–54 | 86.2 (81.3–89.8) | 1.6 (1.4–1.8) *** | 1.8 (1.6–2.0) *** | 15.7 (12.0–20.4) | 0.9 (0.6–1.3) | 0.8 (0.6–1.1) | 21.2 (16.5–26.8) | 0.8 (0.6–1.2) | 0.9 (0.6–1.2) |
| 55–64 | 85.6 (80.1–89.8) | 1.6 (1.4–1.8) *** | 1.7 (1.5–1.9) *** | 16.0 (11.5–21.9) | 0.9 (0.6–1.4) | 0.9 (0.6–1.3) | 18.9 (14.3–24.6) | 0.8 (0.5–1.1) | 0.8 (0.5–1.1) |
| ≧65 | 90.5 (82.9–95.0) | 1.7 (1.5–1.9) *** | 1.8 (1.6–2.0) *** | 23.0 (18.0–35.8) | 1.4 (0.9–2.3) | 1.3 (0.8–2.0) | 28.3 (20.4–37.7) | 1.1 (0.8–1.7) | 1.2 (0.8–1.7) |
| Birth place | |||||||||
| French Guiana | 71.5 (68.1–74.7) | Ref | Ref | 17.2 (13.8–21.2) | Ref | Ref | 23.4 (20.2–27.1) | Ref | Ref |
| Surinam | 83.9 (75.8–89.6) | 1.2 (1.1–1.3) *** | 1.0 (0.9–1.1) | 32.6 (25.2–41.0) | 1.9 (1.4–2.6) *** | 1.4 (1.0–1.9) * | 27.0 (20.2–35.1) | 1.1 (0.8–1.6) | 1.1 (0.8–1.6) |
| Brazil | 76.3 (67.6–83.3) | 1.1 (0.9–1.2) | 0.9 (0.8–1.0) * | 7.8 (4.1–14.2) | 0.4 (0.2–0.9) * | 0.4 (0.2–0.8) * | 19.1 (13.3–26.7) | 0.8 (0.6–1.2) | 0.8 (0.6–1.3) |
| Other South America | 88.9 (69.6–96.6) | 1.2 (1.1–1.4) *** | 1.0 (0.9–1.1) | 31.9 (19.9–46.9) | 1.8 (1.1–3.0) ** | 1.7 (1.1–2.6) * | 27.6 (17.7–40.2) | 1.2 (0.8–1.8) | 1.2 (0.7–1.9) |
| Haïti | 95.1 (90.3–97.6) | 1.3 (1.2–1.4) *** | 1.1 (1.0–1.2) * | 48.9 (41.2–56.6) | 2.8 (2.2–3.7) *** | 2.2 (1.6–3.2) *** | 34.3 (27.2–42.3) | 1.5 (1.1–1.9) ** | 1.3 (0.9–1.8) |
| Caribbean island | 94.6 (88.6–97.5) | 1.3 (1.2–1.4) *** | 1.1 (1.1–1.2) *** | 25.3 (17.1–35.8) | 1.5 (1.0–2.2) | 1.9 (1.3–2.9) *** | 20.6 (13.5–30.2) | 0.9 (0.6–1.3) | 0.9 (0.6–1.5) |
| Europe | 46.7 (40.8–52.7) | 0.7 (0.6–0.8) *** | 0.6 (0.5–0.7) *** | 6.9 (4.2–11.3) | 0.4 (0.2–0.7) *** | 0.6 (0.3–1.1) | 17.0 (12.4–22.8) | 0.7 (0.5–1.0) | 0.8 (0.6–1.2) |
| Asia | 70.9 (43.3–88.6) | 1.0 (0.7–1.4) | 0.8 (0.6–1.1) | 15.6 (4.4–42.6) | 0.9 (0.3–3.0) | 1.4 (0.4–5.2) | 4.6 (1.1–17.6) | 0.2 (0.0–0.8) * | 0.2 (0.1–1.0) |
| Africa | 67.9 (43.3–85.5) | 0.9 (0.7–1.3) | 0.8 (0.6–1.1) | 17.2 (5.3–43.5) | 1.0 (0.3–3.0) | 1.9 (0.6–5.8) | 12.4 (3.1–38.6) | 0.5 (0.1–2.0) | 0.6 (0.2–2.5) |
| Others | 18.0 (2.6–63.9) | 0.3 (0.0–1.4) | 0.2 (0.0–1.1) | 31.7 (4.9–80.5) | 1.8 (0.4–8.3) | 2.4 (0.8–7.7) | 6.1 (0.7–36.6) | 0.3 (0.0–2.0) | 0.2 (0.0–2.0) |
| Region of residence | |||||||||
| Coastal area | 72.5 (69.5–75.2) | Ref | Ref | 18.0 (15.1–21.3) | Ref | Ref | 23.2 (19.4–25.3) | Ref | Ref |
| Low Maroni | 78.6 (73.4–83.0) | 1.1 (1.0–1.2) | 1.1 (1.0–1.2) * | 32.6 (26.2–39.8) | 1.8 (1.4–2.4) *** | 1.8 (1.2–2.7) ** | 28.8 (23.4–34.8) | 1.3 (1.0–1.6) * | 1.3 (1.0–1.7) * |
| High Maroni | 67.2 (57.2–75.8) | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) | 25.0 (18.3–33.1) | 1.4 (1.0–1.9) | 1.9 (1.3–2.9) ** | 25.4 (17.2–36.0) | 1.14 (0.8–1.7) | 1.5 (1.0–2.4) * |
| Low Oyapock | 76.4 (62.8–86.2) | 1.0 (0.9–1.2) | 1.2 (1.0–1.4) * | 12.5 (4.6–29.7) | 0.69 (0.3–1.8) | 1.1 (0.4–3.0) | 27.0 (13.5–9.8) | 1.2 (0.6–2.3) | 1.7 (0.9–3.4) |
| High Oyapock | 31.8 (22.7–42.6) | 0.4 (0.3–0.6) *** | 0.4 (0.3–0.6) *** | 1.6 (0.4–6.7) | 0.1 (0.0–0.4) *** | 0.1 (0.0–0.5) ** | 3.7 (1.3–6.9) | 0.2 (0.1–0.5) *** | 0.2 (0.1–0.6) ** |
| Interior | 60.6 (41.7–76.7) | 0.8 (0.6–1.1) | 0.8 (0.6–1.1) | 0.8 (0.1–6.1) | 0.04 (0.0–0.4) * | 0.1 (0.0–0.7) * | 1.0 (0.1–6.9) | 0.04 (0.0–0.3) * | 0.1 (0.0–0.5) * |
| Type of zone | |||||||||
| Rural | 70.4 (66.7–73.8) | Ref | Ref | 16.9 (14.0–20.2) | Ref | Ref | 19.4 (16.2–23.1) | Ref | Ref |
| Urban | 74.1 (70.9–76.9) | 1.1 (1.0–1.2) | 1.0 (1.0–1.1) | 21.5 (18.3–25.2) | 1.3 (1.0–1.6) * | 1.4 (1.1–1.8) ** | 24.8 (21.7–28.1) | 1.3 (1.0–1.6) * | 1.5 (1.1–1.9) ** |
| Household income, € | |||||||||
| <1000 | 79.9 (75.0–84.1) | Ref | Ref | 31.8 (26.7–37.4) | Ref | Ref | 26.9 (22.2–32.0) | Ref | Ref |
| 1000–2999 | 73.2 (69.1–77.0) | 0.9 (0.8–1.0) * | 1.0 (0.9–1.1) | 19.9 (14.7–26.4) | 0.6 (0.4–0.9) ** | 0.9 (0.7–1.2) | 24.5 (19.7–29.9) | 0.9 (0.7–1.2) | 1.0 (0.7–1.3) |
| 3000–4999 | 63.8 (56.3–70.8) | 0.8 (0.7–0.9) *** | 0.9 (0.8–1.0) | 8.1 (5.0–12.7) | 0.2 (0.1–0.4) *** | 0.5 (0.3–0.8) ** | 17.7 (12.5–24.3) | 0.6 (0.4–1.0) * | 0.8 (0.5–1.2) |
| ≧5000 | 62.0 (52.3–70.9) | 0.8 (0.6–0.9) ** | 0.9 (0.8–1.1) | 8.2 (4.1–15.7) | 0.2 (0.1–0.5) *** | 0.5 (0.3–1.1) | 15.7 (9.4–25.0) | 0.6 (0.3–1.0) * | 0.9 (0.7–1.2) |
| NP | 75.2 (70.1–79.6) | 0.9 (0.8–1.0) | 1.0 (0.9–1.0) | 21.1 (17.1–25.7) | 0.7 (0.5–0.9) ** | 0.7 (0.5–1.0) * | 24.0 (19.8–28.8) | 0.9 (0.7–1.2) | 1.26 (0.8–2.0) |
| Health insurance status | |||||||||
| General social coverage | 69.1 (65.8–72.3) | Ref | Ref | 11.9 (9.4–14.9) | Ref | Ref | 20.2 (17.3–23.5) | Ref | Ref |
| Universal health coverage | 75.6 (71.8–79.1) | 1.1 (1.0–1.2) ** | 1.0 (0.9–1.1) | 26.5 (22.1–31.4) | 2.2 (1.7–3.0) *** | 1.4 (0.9–2.1) | 25.4 (21.5–29.8) | 1.2 (1.0–1.6) * | 1.0 (0.7–1.3) |
| State medical assistance | 90.0 (81.6–94.9) | 1.3 (1.2–1.4) *** | 1.1 (1.0–1.2) * | 51.0 (41.5–60.4) | 4.3 (3.2–5.8) *** | 1.8 (1.2–2.8) ** | 36.5 (27.5–46.6) | 1.8 (1.3–2.5) *** | 1.3 (0.9–1.9) |
*** p < 0.001; ** p < 0.01; * p < 0.05; Ref = reference group (PR = 1).
Figure 4Graphical representation of the correlations between DENV, CHIKV and ZIKV seroprevalences levels; (a) DENV (X) vs. CHIKV (Y); (b) DENV (X) vs. ZIKV (Y); (c) CHIKV (X) vs. ZIKV seroprevalence (Y).
Factors associated with MAYV seropositivity.
| Characteristic | Mayaro | ||
|---|---|---|---|
| Weighted Prevalence % | Univariate | Multivariate | |
| (95% CI) | PR (95% CI) | PR (95% CI) | |
| Sex | |||
| Male | 3.8 [2.9–5.1] | Ref | Ref |
| Female | 2.8 [2.1–3.8] | 0.7 [0.5–1.1] | 0.6 [0.4–1.0] * |
| Age, y | |||
| 2–17 | 0.3 [0.1–1.1] | Ref | Ref |
| 18–34 | 3.0 [2.0–4.6] | 11.3 [2.6–48.5] *** | 13.2 [3.0–58.8] *** |
| 35–44 | 4.4 [2.8–6.9] | 16.5 [3.8–71.2] *** | 26.0 [5.7–118.6] *** |
| 45–54 | 7.3 [4.8–11.0] | 27.4 [6.4–117.2] *** | 37.1 [8.3–165.7] *** |
| 55–64 | 6.0 [3.8–9.2] | 22.4 [5.2–96.6] *** | 44.1 [10.0–194.7] *** |
| ≧65 | 9.2 [4.8–16.7] | 34.4 [7.5–157.9] *** | 75.2 [15.9–354.4] *** |
| Birth place | |||
| French Guiana | 3.5 [2.6–4.6] | Ref | Ref |
| Surinam | 15.4 [10.6–22.0] | 4.4 [2.8–7.0] *** | 1.3 [0.7–2.2] |
| Brazil | 3.5 [1.3–9.2] | 0.9 [0.3–2.8] | 0.6 [0.2–1.9] |
| Others | 1.1 [0.5–2.3] | 0.3 [0.1–0.7] ** | 0.2 [0.1–0.5] *** |
| Region of residence | |||
| Coastal area | 1.6 [1.1–2.4] | Ref | Ref |
| Low Maroni | 9.4 [6.9–12.7] | 5.7 [3.5–9.2] *** | 2.7 [1.5–4.6] *** |
| High Maroni | 12.0 [8.0–17.7] | 7.3 [4.2–12.6] *** | 3.3 [1.8–6.0] *** |
| Low Oyapock | 0.7 [0.1–5.1] | 0.4 [0.1–3.3] | 0.4 [0.0–3.3] |
| High Oyapock | 19.2 [13.2–27.0] | 11.6 [6.9–19.6] *** | 4.9 [2.7–8.9] *** |
| Interior | 16.4 [5.3–40.4] | 9.9 [3.3–30.0] *** | 3.2 [1.0–10.6] * |
| Type of zone | |||
| Rural | 5.8 [4.5–7.5] | Ref | Ref |
| Urban | 2.4 [1.7–3.3] | 0.4 [0.3–0.6] *** | 0.8 [0.5–1.3] |
| Household income, € | |||
| <1000 | 4.2 [2.8–6.1] | Ref | Ref |
| 1000–2999 | 2.4 [1.5–3.7] | 0.6 [0.3–1.0] | 1.3 [0.7–2.3] |
| 3000–4999 | 1.2 [0.4–3.3] | 0.3 [0.1–0.9] * | 1.1 [0.3–3.8] |
| ≧5000 | 2.2 [0.7–7.4] | 0.5 [0.1–1.9] | 3.3 [0.8–13.5] |
| NP | 5.3 [3.9–7.3] | 1.3 [0.8–2.1] | 1.3 [0.8–2.0] |
| Health insurance status | |||
| General social coverage | 1.6 [1.0–2.5] | Ref | Ref |
| Universal health coverage | 5.5 [4.3–7.0] | 3.5 [2.1–6.0] *** | 2.9 [1.6–5.5] *** |
| State medical assistance | 3.2 [1.5–6.8] | 2.0 [0.8–5.0] | 3.7 [1.3–10.1] *** |
*** p < 0.001; ** p < 0.01; * p < 0.05; Ref = reference group (PR = 1).